Yoshimasa Miyagawa

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Kazuhiro Araki, Yoshinori Ito, Ippei Fukada et al. · BMC Cancer · 2018 · 55 citations · Full text

Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel

Yoshimasa Miyagawa, Kazuhiro Araki, Ayako Bun et al. · Clinical Breast Cancer · 2018 · 51 citations · Full text

High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer

Arisa Nishimukai, Tomoko Yagi, Ayako Yanai et al. · Clinical Breast Cancer · 2014 · 48 citations

Breast Oncology, Endocrine-related Cancer, Medicine +10

Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes

Tomoko Higuchi, Arisa Nishimukai, Hiromi Ozawa et al. · The Breast · 2016 · 46 citations · Full text

Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine

Michiko Imamura, Takashi Morimoto, Chiyomi Egawa et al. · Scientific Reports · 2019 · 33 citations · Full text